Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Core Insights - Kymera Therapeutics has initiated dosing in the BroADen Phase 1b clinical trial for KT-621, targeting moderate to severe atopic dermatitis (AD), with data expected in Q4 2025 [1][2] - The company has completed the SAD/MAD dosing in the KT-621 Phase 1 healthy volunteer trial, with results anticipated in June 2025 [1] - Two parallel Phase 2b trials for KT-621 in AD and asthma are planned to commence in Q4 2025 and Q1 2026, respectively [3] Company Overview - Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases [1][8] - The company aims to revolutionize treatment for complex immuno-inflammatory diseases through its unique technology, which offers biologics-like profiles in an oral format [2][4] - KT-621 is the first STAT6-targeted agent in clinical development, with the potential to significantly alleviate the burden of AD through effective oral administration [2][4] Clinical Trial Details - The BroADen Phase 1b trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of KT-621 in approximately 20 adult patients with moderate to severe AD [2] - The primary objective is to demonstrate robust STAT6 degradation and its effects on Th2 biomarkers, alongside clinical endpoints like the Eczema Area and Severity Index (EASI) [2] - The upcoming Phase 2b trials are designed to accelerate the development of KT-621 and facilitate dose selection for subsequent Phase 3 studies across various Th2-related conditions [3] Product Information - KT-621 is a first-in-class, once-daily oral degrader of STAT6, which is crucial for IL-4/IL-13 signaling and Th2 inflammation [4] - Preclinical studies have shown that KT-621 exhibits dupilumab-like activity, indicating its potential effectiveness in treating Th2 diseases [4] - The drug aims to provide a more convenient treatment option compared to injectable biologics, potentially reaching a broader patient population [4][6] Market Context - Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition that significantly impacts patients' quality of life, with a notable unmet need for improved treatment options [6] - Current treatments include topical therapies and injectable biologics, but there remains a significant opportunity for new oral therapies like KT-621 to address this need [6]